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Oligoarticular juvenile idiopathic arthritis (JIA) is a common disease in pediatric rheumatology. The management of oligoarticular
JIA can result in a considerable economic burden. This study is a four-year, retrospective cost identiﬁcation analysis performed to
determine the annual direct cost of care for patients with oligoarticular JIA and possible predictive clinical factors. Direct healthcare
costs were deﬁned as those associated with oﬃce visits, laboratory studies, hospital admissions, joint injections, medications,
infusions, radiology tests, and emergency room visits. Disease characteristics and patient information included ANA status,
gender, age at diagnosis, duration from diagnosis to initial visit during the study period, and whether uveitis had been
diagnosed. We identiﬁed 97 patients with oligoarticular JIA eligible for the study. The median age of diagnosis was 4.3 years.
Positive ANA were noted in 75% of patients. 34% of patients received at least one intra-articular steroid injection. 32% of
patients were prescribed a biologic during the study period, predominantly with other medications, while 23% of patients
received only NSAIDs. 20% of patients were prescribed oral steroids. The average total direct medical cost in this study per year
for an oligoarticular JIA patient was $3929 ± 6985. Medications accounted for 85% of annual direct medical costs. Clinic visits
and laboratory testing accounted for 8% and 5%, respectively. Patient characteristics and demographics were tested for
association with direct medical costs by the Wilcoxon rank sum test and Kruskal-Wallis test. Patients who were ANA positive
had increased annual costs compared to patients who are ANA negative. ANA-positive patients were found to have statistically
signiﬁcant costs, particularly, in laboratory tests, procedural costs, radiology costs, and medication costs. The results reported
here provide information when allocating healthcare resources and a better understanding of the economic impact oligoarticular
JIA has on the United States healthcare system.

1. Introduction
Juvenile idiopathic arthritis (JIA) is characterized by inﬂammation and damage to the joints and aﬀects approximately 1
in 1,000 children worldwide [1]. Being the most common
rheumatic disease in childhood, JIA is a chronic disease that
can have a serious impact on quality of life even when

controlled [2]. Little is known about the economic impact
of oligoarticular JIA [3]. According to the International League of Associations for Rheumatology (ILAR), JIA is classiﬁed into seven categories based on clinical and laboratory
features that present in the ﬁrst 6 months [4]. Oligoarticular
JIA, one of the most common JIA subtypes, aﬀects four or
fewer joints during the ﬁrst 6 months of illness [5].
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Oligoarticular JIA is further divided into two categories, persistent and extended, depending on the number of joints
involved after the initial six-month period. Patients are considered to have persistent oligoarticular JIA if they continue
to have four or fewer joints after the ﬁrst 6 months. Extended
oligoarticular JIA patients have more than 4 joints aﬀected
after the ﬁrst 6 months of symptoms.
Evolving health care reform requires managing direct
costs of care incurred by diﬀerent treatment modalities for
children with arthritis and other chronic illnesses. The multidisciplinary management of oligoarticular JIA, including frequent hospital visits, laboratory evaluation, and medical
treatments, can result in a considerable economic burden.
Data on the cost of JIA are less available than for other illnesses [6]. With the expanded use of biologic agents, drug
costs are beginning to replace inpatient care as the greatest
source of direct medical costs [7]. The economic impact of
JIA and whether it is associated with particular clinical characteristics are not well known [3]. The aim of this study is to
determine the annual direct cost of care for oligoarticular JIA
patients and identify any predictors of increased costs.

2. Methods
A four-year, retrospective cost identiﬁcation analysis was
performed to determine the annual direct cost of care for
patients with oligoarticular JIA and possible predictive clinical factors.
2.1. Patients. Patients meeting ILAR criteria for the diagnoses
of persistent and extended oligoarticular juvenile idiopathic
arthritis [4] between January 2011 and December 2014
followed by the Division of Pediatric Rheumatology at Ann
& Robert H. Lurie Children’s Hospital of Chicago were identiﬁed by extracting diagnosis codes from the electronic medical record (EMR). Those seen less than yearly were excluded,
as they were assessed as being in remission, no longer needing follow-up visits, or lost to follow-up. Patients who carried
an ICD code diagnosis of oligoarticular JIA were reviewed to
ensure they met criteria for diagnosis. Disease characteristics
and patient information extracted from each patient’s record
included ANA status, gender, age at diagnosis, duration from
diagnosis to initial visit during the study period, age at time
of ﬁrst visit, and whether uveitis had been diagnosed. Counts
of active arthritic joints at the start and end of the study
period were obtained. We also extracted data identifying
which patients had joint injections and whether these injections were done in the clinic, operating room, or interventional radiology department.
2.2. Cost Data. Health care costs were measured as a direct
cost to the hospital for acquisition of materials and services.
Direct healthcare costs were deﬁned as those associated with
oﬃce visits, laboratory studies, hospital admissions, procedures such as joint injections, medications, day hospital infusions, radiology tests, and emergency room visits. All costs
were obtained by the hospital’s business analytics
department.
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Costs of outpatient medications were calculated using a
combination of prescriptions sent, (extracted from the
EMR) and formulary pricing. Costs from infusions received
at Lurie Children’s Hospital were obtained via the business
analytics department; infusion center visits were considered
hospital encounters. Our study did not include infusions
done at other centers or through home health since those
costs could not be obtained. Table 1 summarizes the patient
population for this study. Data are expressed as number (percentage) or median (interquartile range).
2.3. Statistical Analyses. All statistical analyses were performed using SAS statistical software (Release 9.4, SAS Institute, Cary, NC). Percentages, median (with interquartile
range), or mean ± SD were used where appropriate to express
disease characteristics, patient demographics, and direct
medical costs. The Wilcoxon rank sum test was used to determine correlations between patient characteristics and direct
medical costs.

3. Results
3.1. Patient Characteristics. We identiﬁed 97 patients (92%
females) with oligoarticular JIA eligible for the study. The
median age of diagnosis and median duration from diagnosis
(in 2011) for patients in our study were 4.3 and 8.2 years,
respectively. Positive anti-nuclear antibodies were noted in
75% of patients. 34% (33 patients) had received at least one
intra-articular steroid injection. Of the patients who received
intra-articular joint injections, 62% (21 patients) had joint
injections performed by interventional radiology, whereas
30% (10 patients) had joint injections in the operating room,
and 6% (2 patients) in our outpatient clinic, respectively. 27%
(26 patients) had a diagnosis of uveitis documented in our
EMR. 76% of patients were classiﬁed as having persistent oligoarticular JIA. A medication proﬁle of the 97 patients is
shown in Table 2. 32% of patients were prescribed a biologic
during the four-year study period, predominantly in conjunction with other medications, while 23% of patients
received only NSAIDs over the four-year period. 20% of
patients were prescribed oral steroids during the study
period.
3.2. Annual Direct Medical Costs and Its Components. Table 3
summarizes annual direct medical costs for patients in our
study by cost components. The average total direct medical
cost in this study per year for an oligoarticular JIA patient
was $3929 ± 6985. Medications (including infusions)
accounted for 85% of annual direct medical costs. Clinic
visits and laboratory testing accounted for 8% and 5%,
respectively. On average, annual clinic visits were $332 with
a standard deviation of $312.
3.3. Predictors of Direct Medical Costs. Patient characteristics
and demographics were tested for association with direct
medical costs by the Wilcoxon rank sum test for all two
group comparisons and the Kruskal-Wallis test for all comparisons with three or more groups. Variables that were evaluated for associations with direct costs included ANA,
gender, diagnosis of uveitis, subtype of oligoarticular JIA,
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Table 1: Patient characteristics (n = 97).

Total number of patients

97

Female (%)
Median age of diagnosis (yrs)
Median duration from diagnosis (yrs) in 2011
ANA positivity (%)
Patients that received intra articular joint injections (%)
Patients with uveitis (%)
Persistent oligoarticular JIA (%)
Extended oligoarticular JIA (%)

92
4.3 (2.5-7.9)
8.2 (5.6-11.6)
75
34
26
76
24

Table 2: Medication proﬁle over a 4-year period (n = 97).

NSAIDs only
NSAIDs and methotrexate
NSAIDs, biologics, and methotrexate
NSAIDs, sulfasalazine, and methotrexate
NSAIDs, biologic, methotrexate, and oral steroids
NSAIDs and sulfasalazine
Other (combination of the above)
Total

Table 3: Annual direct medical costs for patients with oligoarticular
JIA (N = 97).
Costs
Clinic visits
Laboratory
testing
Radiology
Procedural
Medications
Infusions
Total direct
costs

Average cost per person, standard deviation (%
total direct annual cost)
332 ± 312 (8)
197 ± 217 (5)
34 ± 123 (1)
45 ± 122 (1)
2927 ± 4567 (75)
394 ± 2212 (10)
3929 ± 6985 (100)

Data are expressed as number (percentage) or mean ± standard deviation
(SD).

and intra-articular steroid injections. Table 4 lists the
annual direct costs ± SD as well as p values for the associated
variable. The ANA status and oligoarticular JIA subtype were
statistically signiﬁcant, with p values of 0.02 and 0.04, respectively. Patients who were ANA positive had increased annual
costs compared to patients who are ANA negative. ANApositive patients were found to have statistically signiﬁcant
costs, particularly, in laboratory tests (p = 0:08), procedural
costs (p = 0:04), radiology costs (p = 0:06), and medication
costs (p = 0:02). Extended oligoarticular JIA patients had
higher costs than patients classiﬁed as persistent oligoarticular JIA subtype. Extended oligoarticular JIA patients particularly had statistically signiﬁcant medication costs (p = 0:04)

Number of patients

% of patients

21
19
13
9
8
7
20
97

23
20
13
9
8
7
20
100

compared to persistent oligoarticular JIA patients, with medication costs of $3932 ± 3943 and $2613 ± 4725, respectively.
When evaluating costs for the number of arthritic joints at
the start and end of the study, an increase or decrease in joint
count over four years detected no diﬀerence in annual total
direct cost.

4. Discussion
JIA is a complex chronic condition associated with a considerable economic burden to families aﬀected as well as the
health care system. We investigated costs associated with oligoarticular JIA. In our study, the mean annual total cost of
oligoarticular JIA was estimated as $3929 ± 6985. As
expected, the cost of medications, including infusions,
(85%) was the largest contributor for costs. Extended oligoarticular JIA had a statistically signiﬁcant higher mean annual
cost of care than persistent oligoarticular JIA patients. ANA
positivity was also found to be associated with higher annual
costs of care. This result could be explained by the association
of ANA positivity with uveitis, resulting in more aggressive
treatment plans, often including biologic agents.
Our study had cost component results similar to other
cost studies of JIA patients. In previously published studies,
the majority included and categorized costs by the various
subtypes of JIA. Our ﬁndings are similar to studies ﬁnding
that patients with JIA have high costs, particularly, those
related to oﬃce visits, medication costs, and diagnostic testing [3]. An assessment by Minden et al. found that the mean
total direct cost of care in patients with active JIA of any subtype was approximately 3000 euros per year ($3282 in 2017
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Table 4: Annual direct mean costs based on patient characteristics
(via Wilcox rank sum test).
Cost per patient
ANA

0.02

ANA positive

4415 ± 7709

ANA negative

2418 ± 3050

Gender

0.49

Female

4027 ± 7136

Male

2734 ± 3182

Intra-articular steroids

0.82

Received

2642 ± 1777

Not received

4580 ± 8340

Oligoarticular JIA subtype

0.04

Persistent

3671 ± 7527

Extended

4722 ± 4311

Uveitis
3574 ± 7718

No diagnosis of uveitis

4041 ± 3716

Infusions
No infusions

5. Conclusion
0.19

Diagnosis of uveitis

Infusions received

p value

were limited to services provided within our institution. Outside costs such as laboratory studies and infusions were not
included, although most oligoarticular JIA patients do not
receive infusions. This study only evaluated direct costs, not
indirect costs such as time missed from school, transportation costs, or work absences for guardians, which could also
pose a signiﬁcant economic burden. In a United Kingdom
study, it was found that JIA is likely to have a considerable
economic impact, especially with regards to nonhealth care
costs due to its societal impact [6]. We also did not have complete data on uveitis severity, because patients were often
followed by local ophthalmologists, with notes variably sent
to us. This study characterized patients with oligoarthritis.
Future studies will explore the relation of economic burden
to disease severity and evolving practices that includes telemedicine visits, and evolving new therapies.

0.0007
25786 ± 19057
2732 ± 2550

US dollars) [1]. Current data shows that biologics are reducing direct and indirect healthcare costs if one excludes the
costs of the drug itself since the cost of biologics are ten times
as high as conventional drug treatment [8]. A study done in
Turkey found that medications contributed to 90% of health
care costs associated with JIA, where anti-TNF drugs were
the major source of these costs [9]. A United Kingdom study
provided JIA costs during the ﬁrst year of diagnosis and
found that the total direct costs were 3205 US dollars and
3881 US dollars for oligoarticular persistent and oligoarticular extended JIA patients, respectively [10]. This study also
found that costs signiﬁcantly vary according to JIA subtype.
Ours is the ﬁrst study to explore diﬀerences in JIA subtype
and ANA status that were associated with diﬀerent costs.
Results of costing have been similar in studies for other
rheumatologic conditions. In a South Korean cost study for
systemic lupus erythematous patients, the largest component
of direct medical costs were medications, with a mean annual
cost amounted to 3305 US dollars in 2010 [11]. In adult rheumatoid arthritis (RA), a recent study found that costs attributable to RA-speciﬁc therapies, particularly, biologic
therapies, represented almost half of direct four-year costs
[7].
Our study was subject to several limitations. First, data
was primarily extracted from the EMR and was dependent
on proper diagnosis coding, physical examination documentation, procedure coding, and updated medication lists. Provider variability in medication treatment plans and
laboratory evaluations could lead to variability in costs.
Micro costing was performed on prescription drugs ordered
in the EMR, which were assumed to be ﬁlled. Costs extracted

In summary, we identiﬁed the annual direct medical costs for
oligoarticular JIA. The results reported here provide information when allocating healthcare resources and a better
understanding of the economic impact oligoarticular JIA
has on the U.S. healthcare system. Even though oligoarticular
JIA is considered one the more mild subtypes of JIA, it is still
associated with high costs. Our study found that direct medical costs were higher in oligoarticular JIA patients who were
ANA positive or had an extended course and that medications account for over 80% of direct medical costs in patients
with oligoarticular JIA. The costs involved with the care of
JIA patients are important for physicians and policy makers
to consider when making informed decisions about patient
care, especially as targeted drug therapies become more
widely available for children.

Data Availability
The cost data used to support the ﬁndings of this study are
available from the corresponding author upon request.
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